Changing the game: New data on axonal Guillain-Barré syndrome in Mexican adult patients (1048)

Objective: 1. To describe the characteristics of Mexican adult patients with axonal Guillain-Barre syndrome (GBS). 2. To assess the influence of this subtype on the prognosis. Background: In Latin America, most of the evidence on axonal GBS comes from studies in children. One study recently included adult patients with this subtype. However, it has a very small sample size (n=5). In short, in our country and most of the continent, little is known about this subtype in adult patients. Design/Methods: This was a unicenter, ambispective, cohort study (2015–2019). GBS was defined following the Asbury and Cornblath criteria. Electrodiagnosis was made according to the criteria proposed by Hadden and colleagues. Clinical, biochemical and electrodiagnostic parameters were described, compared and then analyzed using a multivariate model for unfavorable outcome (Hughes score ≥3). Only patients who completed a 3-month follow-up were included in this model. Results: 137 patients with GBS were included (92 males; mean age 46.6±16.6). 132 patients (96.3%) underwent an electrodiagnostic assessment. 68 (51.5%) patients were classified as axonal GBS. They were further classified into two groups: acute motor axonal neuropathy (AMAN, n=60, 45.4%) and acute motor and sensory axonal neuropathy (AMSAN, n=8, 6%). Patients with AMAN were significantly younger when compared to patients with AIDP (42.4±14.7 vs 52.5±16.5 years). The total MRC sum score was also significantly lower in AMAN (30.1±16.3 vs 36.4±14.4). Unilateral facial palsy was comparatively less common in AMAN (10% vs 25%). Albuminocytological dissociation was found less frequently in AMAN (41% vs 71%). In the multivariate analysis, AMAN was an independent predictor of an unfavorable outcome (OR: 3.34, 95%-CI: 1.12–9.9, p=0.03). Conclusions: To the best of our knowledge, our cohort of Mexican adult patients with axonal GBS is the largest to date in Latin America. This subtype is an independent predictor of inability to walk independently at 3 months after discharge. Disclosure: Dr. Cervantes Uribe has nothing to disclose. Dr. Delgado-Garcia has received personal compensation in an editorial capacity for Neurology Resident & Fellow Section. Dr. Delgado-Garcia has received research support from Fundacion Carlos Slim. Dr. Lopez has nothing to disclose. Dr. Colunga-Lozano has nothing to disclose. Dr. Garcia Trejo has nothing to disclose. Dr. Bazan has nothing to disclose. Dr. Burgos-Centeno has nothing to disclose. Dr. Fernandez-Valverde has nothing to disclose. Dr. Vargas has nothing to disclose.